ANAPTYSBIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.91 USD | -4.21% |
|
-4.63% | +11.62% |
Financials (USD)
| Sales 2024 * | 41.35M | Sales 2025 * | 23.68M | Capitalization | 653M |
|---|---|---|---|---|---|
| Net income 2024 * | -163M | Net income 2025 * | -208M | EV / Sales 2024 * | 8.48 x |
| Net cash position 2024 * | 303M | Net cash position 2025 * | 251M | EV / Sales 2025 * | 17 x |
| P/E ratio 2024 * |
-4.05
x | P/E ratio 2025 * |
-3.79
x | Employees | 117 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on AnaptysBio, Inc.
More recommendations
More press releases
| 1 day | -4.21% | ||
| 1 week | -4.63% | ||
| Current month | -1.77% | ||
| 1 month | +26.71% | ||
| 3 months | -7.58% | ||
| 6 months | +67.32% | ||
| Current year | +11.62% |
1 week
23.72
25.83
1 month
21.0227.02
Current year
18.4927.50
1 year
13.3627.50
3 years
13.3637.89
5 years
10.0079.09
10 years
10.00134.00
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Faga
CEO | Chief Executive Officer | 44 | 21-11-25 |
Dennis Mulroy
DFI | Director of Finance/CFO | 69 | 20-07-14 |
Paul Lizzul
CTO | Chief Tech/Sci/R&D Officer | 49 | 20-07-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hollings Renton
BRD | Director/Board Member | 77 | 15-06-29 |
Dennis Fenton
BRD | Director/Board Member | 72 | 18-03-04 |
Magda Marquet
BRD | Director/Board Member | 65 | 21-01-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 0 M€ | 0.00% | - | |
| 0.07% | 0 M€ | 0.00% | - | |
| 0.02% | 430 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 23.91 | -4.21% | 271,939 |
| 24-05-23 | 24.96 | -0.32% | 276,389 |
| 24-05-22 | 25.04 | +4.55% | 376,689 |
| 24-05-21 | 23.95 | -4.24% | 433,686 |
| 24-05-20 | 25.01 | -0.24% | 529,193 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotes
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
Calendar
2024-06-12
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
23.91
USD
Average target price
43.78
USD
Spread / Average Target
+83.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.62% | 653M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- ANAB Stock
